A VC who’s backed some of biotech’s billion-dollar-plus startups explains why he sees disagreement about an investment as a sign it’s a killer deal

Krishna Yeshwant GV GV general partner Krishna Yeshwant uses a healthy amount of skepticism when vetting potential companies to invest in. His favorite time to…

Read More A VC who’s backed some of biotech’s billion-dollar-plus startups explains why he sees disagreement about an investment as a sign it’s a killer deal